AU2019234956B2 - Compositions and methods for treating severe constipation - Google Patents

Compositions and methods for treating severe constipation Download PDF

Info

Publication number
AU2019234956B2
AU2019234956B2 AU2019234956A AU2019234956A AU2019234956B2 AU 2019234956 B2 AU2019234956 B2 AU 2019234956B2 AU 2019234956 A AU2019234956 A AU 2019234956A AU 2019234956 A AU2019234956 A AU 2019234956A AU 2019234956 B2 AU2019234956 B2 AU 2019234956B2
Authority
AU
Australia
Prior art keywords
constipation
loperamide
vehicle
dgat1
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019234956A
Other languages
English (en)
Other versions
AU2019234956A1 (en
Inventor
Brian K. Hubbard
Michael H. Serrano-Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serleva Inc
Original Assignee
Serleva Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serleva Inc filed Critical Serleva Inc
Publication of AU2019234956A1 publication Critical patent/AU2019234956A1/en
Application granted granted Critical
Publication of AU2019234956B2 publication Critical patent/AU2019234956B2/en
Assigned to SERLEVA, INC. reassignment SERLEVA, INC. Request for Assignment Assignors: ANJI PHARMACEUTICALS INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019234956A 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation Active AU2019234956B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862644033P 2018-03-16 2018-03-16
US62/644,033 2018-03-16
PCT/US2019/022499 WO2019178492A1 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Publications (2)

Publication Number Publication Date
AU2019234956A1 AU2019234956A1 (en) 2020-10-01
AU2019234956B2 true AU2019234956B2 (en) 2025-01-30

Family

ID=67904819

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019234956A Active AU2019234956B2 (en) 2018-03-16 2019-03-15 Compositions and methods for treating severe constipation

Country Status (18)

Country Link
US (4) US11224590B2 (https=)
EP (1) EP3765012B1 (https=)
JP (1) JP7527984B2 (https=)
KR (1) KR102747096B1 (https=)
CN (1) CN111936137B (https=)
AU (1) AU2019234956B2 (https=)
BR (1) BR112020018790A2 (https=)
DK (1) DK3765012T3 (https=)
EA (1) EA202092190A1 (https=)
FI (1) FI3765012T3 (https=)
IL (1) IL277332B2 (https=)
MX (1) MX2020009604A (https=)
MY (1) MY205335A (https=)
PE (1) PE20210158A1 (https=)
PH (1) PH12020551468A1 (https=)
SG (1) SG11202008971VA (https=)
TW (1) TWI704917B (https=)
WO (1) WO2019178492A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора
KR20220052459A (ko) 2020-10-21 2022-04-28 주식회사 엘지에너지솔루션 전극 탭 고정부를 포함하는 용접장치 및 이를 이용한 전극 탭 용접 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126957A2 (en) * 2006-03-31 2007-11-08 Novartis Ag New compounds
WO2008148849A2 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3225997A (en) 1996-05-30 1998-01-05 Trustees Of Columbia University In The City Of New York, The Dna encoding acylcoenzyme a: cholesterol acyltransferase and uses thereof
ATE406448T1 (de) 1998-06-24 2008-09-15 David Gladstone Inst Diacylglycerin o-acyltransferase
US20030167483A1 (en) 1998-06-24 2003-09-04 Farese Robert V. Diacylglycerol O-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US20030154504A1 (en) 1998-06-24 2003-08-14 Farese Robert V. Methods and compositions for modulating carbohydrate metabolism
US6100077A (en) 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6444427B1 (en) 2000-07-11 2002-09-03 The Regents Of The University Of California Polymorphisms in a diacylglycerol acyltransferase gene, and methods of use thereof
JP4164645B2 (ja) 2002-08-09 2008-10-15 株式会社大塚製薬工場 Ｄｇａｔ阻害剤
RU2342388C2 (ru) 2002-11-22 2008-12-27 Джапан Тобакко Инк. Конденсированные бициклические азотсодержащие гетероциклы, обладающие dgat ингибирующим действием
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
AR044152A1 (es) 2003-05-09 2005-08-24 Bayer Corp Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
WO2005013907A2 (en) 2003-08-07 2005-02-17 Japan Tobacco Inc. Pyrrolo[1,2-b]pyridazine derivatives
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
JP2005206492A (ja) 2004-01-21 2005-08-04 Sankyo Co Ltd スルホンアミド化合物
AU2005209115A1 (en) 2004-01-30 2005-08-11 Japan Tobacco Inc. Anorectic compounds
JP2006045209A (ja) 2004-07-02 2006-02-16 Sankyo Co Ltd ウレア誘導体
WO2006004200A1 (ja) 2004-07-02 2006-01-12 Sankyo Company, Limited ウレア誘導体
WO2006019020A1 (ja) 2004-08-16 2006-02-23 Sankyo Company, Limited 置換されたウレア化合物
WO2006044775A2 (en) 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
BRPI0519058A2 (pt) 2004-12-14 2008-12-23 Astrazeneca Ab composto ou um sal prà-droga farmaceuticamente aceitÁvel do mesmo, mÉtodos para produzir uma inibiÇço da atividade de dgat1 e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composiÇço farmacÊutica, e, processo para preparar um composto
WO2006113919A2 (en) 2005-04-19 2006-10-26 Bayer Pharmaceuticals Corporation Aryl alkyl acid derivatives for and use thereof
WO2007002740A2 (en) 2005-06-28 2007-01-04 E. I. Du Pont De Nemours And Company Buffer compositions
GB0611506D0 (en) 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
WO2009112445A1 (en) * 2008-03-10 2009-09-17 Novartis Ag Method of increasing cellular phosphatidyl choline by dgat1 inhibition
US8324241B2 (en) 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
NZ602125A (en) * 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
CN102869645A (zh) * 2010-04-08 2013-01-09 美迪诺亚公司 用于治疗肠易激综合征的方法和组合物
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013169648A1 (en) * 2012-05-07 2013-11-14 Novartis Ag Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
MX2015002210A (es) * 2012-08-29 2015-05-08 Salix Pharmaceuticals Inc Composiciones laxantes y metodos para tratar estreñimiento y enfermedades y condiciones gastrointestinales relacionadas.
BR112016015851A2 (pt) * 2014-01-09 2017-08-08 Sanofi Sa Formulações farmacêuticas estabilizadas de insulina aspart
EA202092190A1 (ru) 2018-03-16 2020-11-19 Анджи Фармасьютикалз Инк. Композиции и способы для лечения сильного запора

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007126957A2 (en) * 2006-03-31 2007-11-08 Novartis Ag New compounds
WO2008148849A2 (en) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Piperidine/piperazine derivatives
WO2013130370A2 (en) * 2012-03-01 2013-09-06 Merck Sharp & Dohme Corp. Compounds as dgat-1 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Denison et al., "Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study," Diabetes Obes Metab 15(2):136-143 (2012). *
KENNETH KULMATYCKI ET AL: "Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor", INT J CLIN PHARMACOL THER, vol. 53, no. 05, pgs. 345-355. DOI: 10.5414/CP202275. *

Also Published As

Publication number Publication date
MY205335A (en) 2024-10-16
US20240293376A1 (en) 2024-09-05
US11224590B2 (en) 2022-01-18
TWI704917B (zh) 2020-09-21
US20190282549A1 (en) 2019-09-19
US20220193044A1 (en) 2022-06-23
DK3765012T3 (da) 2026-04-27
EP3765012B1 (en) 2026-03-04
BR112020018790A2 (pt) 2020-10-13
JP7527984B2 (ja) 2024-08-05
US20260000651A1 (en) 2026-01-01
KR20200136428A (ko) 2020-12-07
EP3765012A1 (en) 2021-01-20
MX2020009604A (es) 2023-01-25
CN111936137A (zh) 2020-11-13
KR102747096B1 (ko) 2024-12-26
PE20210158A1 (es) 2021-01-26
SG11202008971VA (en) 2020-10-29
EP3765012A4 (en) 2021-12-15
WO2019178492A1 (en) 2019-09-19
JP2021518431A (ja) 2021-08-02
IL277332B2 (en) 2025-01-01
IL277332B1 (en) 2024-09-01
CN111936137B (zh) 2023-09-08
EA202092190A1 (ru) 2020-11-19
IL277332A (en) 2020-10-29
US12343334B2 (en) 2025-07-01
FI3765012T3 (fi) 2026-04-17
PH12020551468A1 (en) 2021-09-01
CA3093970A1 (en) 2019-09-19
AU2019234956A1 (en) 2020-10-01
TW201944995A (zh) 2019-12-01
US11819495B2 (en) 2023-11-21

Similar Documents

Publication Publication Date Title
US20260000651A1 (en) Compositions and methods for treating severe constipation
KR102041654B1 (ko) 액체 제형
CN106999475B (zh) 异噁唑啉化合物用于治疗蠕形螨病的用途
TW202011965A (zh) 嗜中性球彈性蛋白酶抑制劑在肝病中之用途
WO2008031014A1 (en) Method for reducing or alleviating inflammation in the digestive tract
KR20250057847A (ko) 경구 전달용 조성물
CA3093970C (en) Compositions and methods for treating severe constipation
AU2021336289A9 (en) Ionic liquid formulations for treating diabetes
CN117695277B (zh) 苯丙酸类似物的光学异构体组合物治疗或预防代谢紊乱中的用途
US20120041228A1 (en) Pharmaceutical composition for ameliorating and/or preventing leptin resistance, and use thereof
JPWO2004026296A1 (ja) 抗ストレス性疾患組成物
WO2024169938A1 (en) Compositions and methods for treating liver diseases
CN119745874A (zh) 甲苯咪唑在制备治疗代谢相关脂肪性肝病的药物中的应用
EP1990053A1 (en) Pharmaceutical composition for enhancing adiponectin production
JP2011032267A (ja) １１βＨＳＤ１阻害剤およびその用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SERLEVA, INC.

Free format text: FORMER OWNER(S): ANJI PHARMACEUTICALS INC.